Inhibiting RORγt/Th17 axis for autoimmune disorders

Area of Science:

• Immunology
• Pharmacology
• Autoimmune Diseases

Background:

• Interleukin-17 (IL-17) pathway is implicated in chronic inflammation and autoimmune disorders.
• Recent clinical trial successes with IL-17 antibodies for psoriasis validate this pathway as a therapeutic target.

Purpose of the Study:

• To review strategies for inhibiting the IL-17 pathway.
• To explore the development of orally available small molecules targeting IL-17 production or signaling.
• To emphasize retinoic-acid-related orphan nuclear receptor RORγt as a key therapeutic target.

Main Methods:

• Review of recent clinical trial data for IL-17 inhibitors.
• Analysis of drug discovery approaches for small molecule inhibitors.
• Focus on the role of RORγt in Th17 cell regulation.

Main Results:

• Antibodies targeting IL-17 or its receptor show success in late-stage clinical trials for psoriasis.
• This validates the IL-17 pathway as a therapeutic target for chronic inflammation and autoimmunity.
• RORγt emerges as a master regulator of Th17 cells, presenting a promising target for drug development.

Conclusions:

• Inhibitors of the IL-17 pathway represent a new therapeutic modality for autoimmune disorders.
• Drug discovery efforts are encouraged for orally available small molecules targeting IL-17 production or signaling.
• Inhibiting RORγt is a key strategy for treating multiple autoimmune diseases by modulating Th17 cell activity.